As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 3/21/24  Nasdaq Stock Market LLC           25-NSE©                2:5K   DMK Pharmaceuticals Corp.                                  
  2/7/24  DMK Pharmaceuticals Corp.         8-K:3        2/6/24   10:186K                                   Qes, LLC/FA              
  2/6/24  Intracoastal Capital, LLC         SC 13G/A               1:54K  DMK Pharmaceuticals Corp.         EdgarAgents LLC/FA       
          Daniel B. Asher³
          Mitchell P. Kopin³
  2/5/24  DMK Pharmaceuticals Corp.         8-K:1,7,8,9  2/2/24   11:230K                                   Quality Edgar - QES/FA   
 1/31/24  DMK Pharmaceuticals Corp.         8-K:5       1/25/24   10:195K                                   Qes, LLC/FA              
 1/23/24  DMK Pharmaceuticals Corp.         DEFA14A                1:48K                                    Qes, LLC/FA              
 1/23/24  DMK Pharmaceuticals Corp.         8-K:3,5,9   1/22/24   11:361K                                   Qes, LLC/FA              
  1/3/24  DMK Pharmaceuticals Corp.         DEFA14A                1:29K                                    Qes, LLC/FA              
  1/3/24  DMK Pharmaceuticals Corp.         8-K:5,8    12/28/23   10:191K                                   Qes, LLC/FA              
  1/3/24  DMK Pharmaceuticals Corp.         8-K:7,9      1/3/24   11:4.1M                                   Qes, LLC/FA              
12/21/23  DMK Pharmaceuticals Corp.         8-K:1,8,9  12/15/23   11:227K                                   Quality Edgar - QES/FA   
 12/4/23  DMK Pharmaceuticals Corp.         DEFA14A                1:31K                                    Qes, LLC/FA              
 12/4/23  DMK Pharmaceuticals Corp.         8-K:5,8    11/30/23   10:187K                                   Qes, LLC/FA              
11/28/23  DMK Pharmaceuticals Corp.         8-K:1,8,9  11/21/23   11:263K                                   Qes, LLC/FA              
11/15/23  DMK Pharmaceuticals Corp.         DEFA14A                1:101K                                   Qes, LLC/FA              
11/15/23  DMK Pharmaceuticals Corp.         DEFA14A                1:16K                                    Qes, LLC/FA              
11/15/23  DMK Pharmaceuticals Corp.         8-K:5,8     11/9/23   10:187K                                   Qes, LLC/FA              
11/15/23  DMK Pharmaceuticals Corp.         DEFA14A                1:26K                                    Qes, LLC/FA              
11/14/23  DMK Pharmaceuticals Corp.         8-K:2,9    11/14/23   11:261K                                   Qes, LLC/FA              
11/14/23  DMK Pharmaceuticals Corp.         10-Q        9/30/23   79:7.6M                                   Qes, LLC/FA              

____________
¹	Filing/Form Types:
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	10-Q	Quarterly Report — Form 10-Q.
	25-NSE	Notice by a Securities Exchange of the Removal from Listing and Registration of Matured, Redeemed or Retired Securities — Form 25.
	DEFA14A	Definitive Additional Proxy Soliciting Material — Schedule 14A.
	SC 13G	Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G.
	/A	Amendment to, or Amended version of, a previous Filing of this Type.
	©	This Filing was a Confirming copy.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.